Head-to-head · The Match Score
Vaylen vs Invyncible
Both scored on the same six-factor Match Score. Vaylen wins this matchup with a 87 to 60 edge.
Vaylen
#8 · Grade B+
People who want maximum options — injectable, oral, compounded or brand — in one LegitScript-certified place.
Visit VaylenInvyncible
#302 · Grade C
People who want corporate-parent-disclosed Florida GLP-1 platform with LegitScript seal.
Visit InvyncibleFactor by factor
The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.
Price, coverage & formulary
| Detail | Vaylen | Invyncible |
|---|---|---|
| Semaglutide | $179/mo | $192/mo (0.5 mg dose, compounded) |
| Tirzepatide | $239/mo | $210/mo (compounded) |
| Coverage | All 50 states | 40 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injectable only |
| Match Score | 87 · B+ | 60 · C |
Vaylen edges out Invyncible, 87 to 60 on the default Match Score. One of the widest formularies on the board — both molecules, an oral route, and brand access, all nationwide.
Invyncible is still a fair pick if its strengths line up with yours — best for: People who want corporate-parent-disclosed Florida GLP-1 platform with LegitScript seal.
Worth a look either way: our overall #1 pick is CoreAge Rx (Match Score 91) — nationwide access, both molecules at one flat price, easy to cancel. Or take the 6-question quiz to see your personalized match.
Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.
More head-to-heads
- Vaylen vs CoreAge Rx
- Vaylen vs Strut Health
- Vaylen vs HealthRX
- Vaylen vs ShedRx
- Vaylen vs Ondra Health
- Vaylen vs Enhance MD
Or browse alternatives to Vaylen and all comparisons.
Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.